Genmab — September 2024
-
can Mette not say a few words about Danish biotechs like Xi did for chinese stocks...
https://x.com/bespokeinvest/status/1839669635307708839 -
Stærke data https://finance.yahoo.com/news/darzalex-daratumumab-based-maintenance-regimens-170500800.html Baren er høj til hexaCD38
-
https://finance.yahoo.com/news/darzalex-faspro-based-quadruplet-regimen-170000742.html Lidt mere af fsamme skuffe.
-
Jo jo, men det vidste vi jo at Perseus og Cepheus havde stærke data. Erzotabart i combi er vi slet ikke nået til endnu. H2H studiet er kun mono for begge stoffer. Hvis bare erzo er dara overlegent i mono og hvis sikkerhedsprofilen er god, så er der ingen tvivl om at erzo i kombi også bliver overlegen.
-
Yes, hexabody cd38 = erzotabart. Man ændrede måden at navngive antistoffer på i 2021. The revised system was approved and adopted by the WHO at the 73rd INN Consultation held in October 2021, and the radical decision was made to discontinue the use of the well-known stem -mab in naming new antibody-based drugs and going forward, to replace it with four new stems: -tug, -bart, -mig, and -ment.
-
-
Godmorgen.
-
DARZALEX
(daratumumab) subcutaneous (SC) formulation-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned https://www.globenewswire.com/en/news-release/2024/09/27/2954641/0/en/DARZALEX-daratumumab-subcutaneous-SC-formulation-based-quadruplet-regimen-significantly-improves-minimal-residual-disease-negativity-for-newly-diagnosed-multiple-myeloma-patients-f.html -
IMS 2024 – Darzalex fights back against Sarclisa https://www.oncologypipeline.com/apexonco/ims-2024-darzalex-fights-back-against-sarclisa
-
Carvykti med gode 3 års data i second line https://finance.yahoo.com/news/carvykti-first-only-cell-therapy-203000097.html
-
After Sanofi's first-line myeloma nod, J&J strikes back with new tranche of Darzalex data https://www.fiercepharma.com/pharma/after-sanofis-first-line-myeloma-nod-jj-strikes-back-new-tranche-darzalex-data
-
Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on tisotumab vedotin state of art
Therapeutic Advances in Medical Oncology https://journals.sagepub.com/doi/10.1177/17588359241277647
god weekend
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind